In contrast, it has been shown that the inactivation of CCR2 inhibits NASH in the liver [48] and that the genetic deletion of MCP-1 and CCR2 attenuates obesity and improves insulin resistance and hepatic steatosis [16,17]. Here, CCL2 is linked to fatty liver disease.